Press Releases

Press Releases
Date Title and Summary View
Mar 6, 2018 Advances Strategy to Become a Leader in Global Cellular Immunotherapy Immediately Adds Late-Stage Therapy JCAR017, an Expected Growth Driver From 2020 and Beyond with Potential Global Peak Sales of Approximately $3B SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation...
Mar 5, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Juno Therapeutics, Inc. at a price of $87.00 per share, net to the seller in cash, without interest and less required withholding taxes, ...
Feb 27, 2018 Conference call scheduled for today at 5:30 p.m. ET SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ...
Feb 27, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.cel...
Feb 21, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by Celgene's wholly owned subsidiary, Blue Magpie Corporation, for all ...
Feb 17, 2018 RELIEF™ trial demonstrated statistically significant reductions in oral ulcers with apremilast 30 mg versus placebo through week 12 Significant improvements in key secondary endpoints, including oral ulcer pain, overall disease activity and quality of life Data presented at t...
Feb 15, 2018 Data shared at the 13th Congress of ECCO Phase III program with OTEZLA (apremilast) in ulcerative colitis expected to begin in 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) announced that data from a randomized, placebo-contro...
Feb 15, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced the election of John Weiland to its Board of Directors. Mr. Weiland has over 30 years in the healthcare industry and was most recently the President and Chief Operating Officer of C. R. Bard, Inc. (Bard), with worldwide re...
Feb 14, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced the Company's Board of Directors authorized the repurchase of an additional $5 billion of the Company's common stock. This open-ended program is effective immediately. Purchases may be made in the open market or in privately ...
Feb 9, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of four series of senior unsecured notes for an aggregate principal amount of $4.5 billion. Of these notes, $500 million will mature in 2021 and will bear interest at an annual rate of 2.875 percent, $1.0 bill...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase